Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1300 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	I
2	2	119THCONGRESS
3	3	1
4	4	STSESSION H. R. 1300
5	5	To amend title XXVII of the Public Health Service Act to require group
6	6	health plans and health insurance issuers offering group or individual
7	7	health insurance coverage to provide coverage for prostate cancer
8	8	screenings without the imposition of cost-sharing requirements, and for
9	9	other purposes.
10	10	IN THE HOUSE OF REPRESENTATIVES
11	11	FEBRUARY13, 2025
12	12	Mr. D
13	13	UNNof Florida (for himself, Ms. CLARKEof New York, Mr. MURPHY,
14	14	and Mr. C
15	15	ARTERof Louisiana) introduced the following bill; which was
16	16	referred to the Committee on Energy and Commerce
17	17	A BILL
18	18	To amend title XXVII of the Public Health Service Act
19	19	to require group health plans and health insurance
20	20	issuers offering group or individual health insurance cov-
21	21	erage to provide coverage for prostate cancer screenings
22	22	without the imposition of cost-sharing requirements, and
23	23	for other purposes.
24	24	Be it enacted by the Senate and House of Representa-1
25	25	tives of the United States of America in Congress assembled, 2
26	26	VerDate Sep 11 2014 01:36 Mar 11, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1300.IH H1300
27	27	kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
28	28	•HR 1300 IH
29	29	SECTION 1. SHORT TITLE. 1
30	30	This Act may be cited as the ‘‘Prostate-Specific Anti-2
31	31	gen Screening for High-risk Insured Men Act’’ or the 3
32	32	‘‘PSA Screening for HIM Act’’. 4
33	33	SEC. 2. FINDINGS. 5
34	34	Congress finds the following: 6
35	35	(1) Prostate cancer is the second leading cause 7
36	36	of cancer death in men in the United States with 1 8
37	37	in 44 men dying from prostate cancer and more 9
38	38	than 35,700 men estimated to die from prostate 10
39	39	cancer in 2025. 11
40	40	(2) Prostate cancer is the second most com-12
41	41	monly diagnosed cancer in the Nation with 1 in 8 13
42	42	men being diagnosed in their lifetimes, 3.3 million 14
43	43	men in the United States living with a diagnosis, 15
44	44	and over 310,000 men estimated to be diagnosed in 16
45	45	2025. 17
46	46	(3) The survival rate for prostate cancer diag-18
47	47	nosed in early stage is near 100 percent but prostate 19
48	48	cancer diagnosed in late stage has only a 37 percent 20
49	49	survival rate. 21
50	50	(4) There are few, if any, symptoms of prostate 22
51	51	cancer before it reaches late stage. 23
52	52	(5) African-American men have a disproportion-24
53	53	ately higher rate of prostate cancer and are 70 per-25
54	54	cent more likely to be diagnosed with prostate can-26
55	55	VerDate Sep 11 2014 01:36 Mar 11, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H1300.IH H1300
56	56	kjohnson on DSK7ZCZBW3PROD with $$_JOB 3
57	57	•HR 1300 IH
58	58	cer than White men, with 1 in 6 African-American 1
59	59	men developing prostate cancer in their lifetimes. 2
60	60	(6) African-American men are 2.1 times more 3
61	61	likely to die from prostate cancer than White men. 4
62	62	(7) Men with a father or brother with prostate 5
63	63	cancer are more than twice as likely to be diagnosed 6
64	64	with prostate cancer than men without a family his-7
65	65	tory. 8
66	66	(8) The common clinical definition for men at 9
67	67	high-risk of prostate cancer includes African-Amer-10
68	68	ican men and men with a family history. 11
69	69	(9) Most of the major cancer and urological so-12
70	70	cieties recommend beginning screening discussions 13
71	71	earlier for African-American men and those with a 14
72	72	family history of prostate cancer. 15
73	73	(10) The United States Preventive Services 16
74	74	Task Force has encouraged research on screening 17
75	75	African-American men, including whether to screen 18
76	76	African-American men at younger ages, and has 19
77	77	identified this research as a high-priority cancer re-20
78	78	search gap. 21
79	79	(11) Barriers to screening should be minimized 22
80	80	for high-risk men in order to catch asymptomatic 23
81	81	prostate cancer before it metastasizes and the sur-24
82	82	vival rate is dramatically reduced. 25
83	83	VerDate Sep 11 2014 01:36 Mar 11, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1300.IH H1300
84	84	kjohnson on DSK7ZCZBW3PROD with $$_JOB 4
85	85	•HR 1300 IH
86	86	(12) The cost of treating metastatic prostate 1
87	87	cancer in the United States health care system is 2
88	88	hundreds of millions of dollars more annually than 3
89	89	the cost of treating localized, early-stage cancer. 4
90	90	SEC. 3. REQUIREMENT FOR GROUP HEALTH PLANS AND 5
91	91	HEALTH INSURANCE ISSUERS OFFERING 6
92	92	GROUP OR INDIVIDUAL HEALTH INSURANCE 7
93	93	COVERAGE TO PROVIDE COVERAGE FOR 8
94	94	PROSTATE CANCER SCREENINGS WITHOUT 9
95	95	IMPOSITION OF COST-SHARING REQUIRE-10
96	96	MENTS. 11
97	97	(a) I
98	98	NGENERAL.—Subsection (a) of section 2713 of 12
99	99	the Public Health Service Act (42 U.S.C. 300gg–13) is 13
100	100	amended to read as follows: 14
101	101	‘‘(a) C
102	102	OVERAGE OF PREVENTIVEHEALTHSERV-15
103	103	ICES.— 16
104	104	‘‘(1) I
105	105	N GENERAL.—A group health plan and a 17
106	106	health insurance issuer offering group or individual 18
107	107	health insurance coverage shall, at a minimum, pro-19
108	108	vide coverage for and shall not impose any cost-shar-20
109	109	ing requirements for— 21
110	110	‘‘(A) evidence-based items or services that 22
111	111	have in effect a rating of ‘A’ or ‘B’ in the cur-23
112	112	rent recommendations of the United States Pre-24
113	113	ventive Services Task Force; 25
114	114	VerDate Sep 11 2014 01:36 Mar 11, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H1300.IH H1300
115	115	kjohnson on DSK7ZCZBW3PROD with $$_JOB 5
116	116	•HR 1300 IH
117	117	‘‘(B) immunizations that have in effect a 1
118	118	recommendation from the Advisory Committee 2
119	119	on Immunization Practices of the Centers for 3
120	120	Disease Control and Prevention with respect to 4
121	121	the individual involved; 5
122	122	‘‘(C) with respect to infants, children, and 6
123	123	adolescents, evidence-informed preventive care 7
124	124	and screenings provided for in the comprehen-8
125	125	sive guidelines supported by the Health Re-9
126	126	sources and Services Administration; 10
127	127	‘‘(D) with respect to women, such addi-11
128	128	tional preventive care and screenings not de-12
129	129	scribed in subparagraph (A) as provided for in 13
130	130	comprehensive guidelines supported by the 14
131	131	Health Resources and Services Administration 15
132	132	for purposes of this subparagraph; and 16
133	133	‘‘(E) with respect to men who are age 40 17
134	134	and over and are at high risk of developing 18
135	135	prostate cancer (including African-American 19
136	136	men and men with a family history of prostate 20
137	137	cancer (as defined in paragraph (2))), such ad-21
138	138	ditional evidence-based preventive care and 22
139	139	screenings not described in subparagraph (A) 23
140	140	for prostate cancer. 24
141	141	VerDate Sep 11 2014 01:36 Mar 11, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H1300.IH H1300
142	142	kjohnson on DSK7ZCZBW3PROD with $$_JOB 6
143	143	•HR 1300 IH
144	144	‘‘(2) MEN WITH A FAMILY HISTORY OF PROS -1
145	145	TATE CANCER DEFINED .—For purposes of para-2
146	146	graph (1)(E), the term ‘men with a family history 3
147	147	of prostate cancer’ means men who have a first-de-4
148	148	gree relative— 5
149	149	‘‘(A) who was diagnosed with prostate can-6
150	150	cer; 7
151	151	‘‘(B) who developed prostate cancer; 8
152	152	‘‘(C) whose death was a result of prostate 9
153	153	cancer; 10
154	154	‘‘(D) who have been diagnosed with a can-11
155	155	cer known to be associated with increased risk 12
156	156	of prostate cancer; or 13
157	157	‘‘(E) who has a genetic alteration known to 14
158	158	be associated with increased risk of prostate 15
159	159	cancer. 16
160	160	‘‘(3) C
161	161	LARIFICATION REGARDING BREAST CAN -17
162	162	CER SCREENING, MAMMOGRAPHY, AND PREVENTION 18
163	163	RECOMMENDATIONS .—For the purposes of this Act, 19
164	164	and for the purposes of any other provision of law, 20
165	165	the current recommendations of the United States 21
166	166	Preventive Service Task Force regarding breast can-22
167	167	cer screening, mammography, and prevention shall 23
168	168	be considered the most current other than those 24
169	169	issued in or around November 2009. 25
170	170	VerDate Sep 11 2014 01:36 Mar 11, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H1300.IH H1300
171	171	kjohnson on DSK7ZCZBW3PROD with $$_JOB 7
172	172	•HR 1300 IH
173	173	‘‘(4) RULE OF CONSTRUCTION .—Nothing in 1
174	174	this subsection shall be construed to prohibit a plan 2
175	175	or issuer from providing coverage for services in ad-3
176	176	dition to those recommended by the United States 4
177	177	Preventive Services Task Force or to deny coverage 5
178	178	for services that are not recommended by such Task 6
179	179	Force.’’. 7
180	180	(b) E
181	181	FFECTIVEDATE.—The amendment made by 8
182	182	subsection (a) shall apply with respect to plan years begin-9
183	183	ning on or after January 1, 2026. 10
184	184	Æ
185	185	VerDate Sep 11 2014 01:36 Mar 11, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6301 E:\BILLS\H1300.IH H1300
186	186	kjohnson on DSK7ZCZBW3PROD with $$_JOB